Migrastatin analogues target fascin to block tumour metastasis

By Lin Chen, Shengyu Yang, J. Jakoncic, J. J. Zhang, Xin-Yun Huang. Nature, 2011

134 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Spectroscopy

View Paper: https://www.semanticscholar.org/paper/b08f7d120bf22461b9c3cdaffd54b2177e79e3ba

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. R. Weinberg
2. Scott Valastyan
3. Lisa M. Coussens
4. Y. Fouad
5. C. Aanei
6. D. Hanahan
7. B. Ruffell
8. J. P. Thiery

In Oncology

1. R. Weinberg
2. Scott Valastyan
3. Lisa M. Coussens
4. M. Nieto
5. D. Hanahan
6. Y. Fouad
7. C. Aanei
8. Zena Werb

Citations in the corpus

• Tumor Metastasis: Molecular Insights and Evolving Paradigms (2011, background): “Unfortunately, however, the rationale behind many targeted agents that were designed to impair carcinoma metastasis, such as MMP inhibitors, the Axl kinase inhibitor R428, miR-10b antagonists, and the fascin inhibitor Migrastatin, is incompatible with these clinical observations, as these compounds ”